Wednesday, July 8, 2026

Patent intelligence · US

US 10039738

Ulcer treatment

granted A61KA61K31/10A61K31/105A61K31/352
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 12
Applicant portfolio 3,720
Patent details — US 10039738
Jurisdiction
US
Status
granted
Grant date
Aug 7, 2018
Expiration
Aug 2, 2038
Claims
9
CPC classes
A61K, A61K31/10, A61K31/105, A61K31/352
View on Google Patents ↗

Quick answer

US 10039738 (Ulcer treatment) is held by UNITED ARAB EMIRATES UNIVERSITY. Status: granted. Granted Aug 7, 2018. Expires Aug 2, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
9
CPC classes
A61K, A61K31/10, A61K31/105, A61K31/352, A61P, A61P1/04

More from UNITED ARAB EMIRATES UNIVERSITY

Related pharmaceutical patents in our USPTO index.

  1. US 12419873

    Use of JAK inhibitors in preparation of drugs for treating JAK kinase-related diseases

    ZHUHAI UNITED LABORATORIES CO., LTD. · Expires Sep 18, 2045

    granted
  2. US 12419941

    Poultry drinking water-based vaccine delivery system and method

    The United States of America, as represented by the Secretary of Agriculture · Expires Sep 18, 2045

    granted
  3. US 12415845

    Methods of producing T cell populations using hydroxycitric acid and/or a salt thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Expires Sep 11, 2045

    granted
  4. US 12410240

    Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Expires Sep 4, 2045

    granted
  5. US 12410259

    CD47 targeted therapies for the treatment of infectious disease

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Expires Sep 4, 2045

    granted
  6. US 12404317

    T cell receptors recognizing MHC class II-restricted MAGE-A3

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Expires Aug 28, 2045

    granted
  7. US 12397066

    Delivery of gene therapy treatments

    United States Government as represented by the Department of Veterans Affairs · Expires Aug 21, 2045

    granted
  8. US 12398123

    Chemical inhibition of the E3 ligase subunit FBXO7 confers neuroprotection and anti-inflammatory activity by stabilizing mitochondria

    United States Government as represented by the Department of Veterans Affairs · Expires Aug 21, 2045

    granted

Frequently asked questions

What is US patent 10039738?

US 10039738 (Ulcer treatment) is held by UNITED ARAB EMIRATES UNIVERSITY. Status: granted. Granted Aug 7, 2018. Expires Aug 2, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10039738?

UNITED ARAB EMIRATES UNIVERSITY is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3,720 pharmaceutical patents for this assignee.

When does US 10039738 expire?

Our index shows an expiration date of Aug 2, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.